The US Food and Drug Administration has published final guidance on cybersecurity controls manufactures should build into their medical devices in order to ensure proper safety and functionality—and to meet premarket review scrutiny. The new guidance applies to all major US premarket submissions including 510(k) premarket notifications, premarket approval (PMA) applications, de novo and product development protocol (PDP) submissions, and Humanitarian Device Exemption (HDE) submissions.